Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Study type
- Clinical guideline
- Study name
- ESMO Immunotherapy Toxicities 2022
- Design
- Clinical guideline (ESMO Clinical Practice Guideline) prepared by the ESMO Guidelines Committee
- Source
- Annals of Oncology · 2022
In plain words
This article is a clinical guideline from the European Society for Medical Oncology (ESMO) on the diagnosis, treatment and follow-up of side effects caused by immunotherapy (treatments that work through the immune system). The details of the recommendations are not given in the available record and should be checked in the full text of the paper. If you notice any new symptom during treatment, tell your treating doctor.
Clinical significance and place in guidelines
This document is an official ESMO guideline on the management of immunotherapy toxicities. The PubMed record contains neither an abstract nor the text of the recommendations, so its impact on clinical practice and the levels of evidence of the recommendations cannot be determined from this record. For clinical use, the full text should be consulted and whether the guideline is still current should be checked.
Limitations
This card is based only on the bibliographic information of the PubMed record, and because the record had no abstract, the recommendations and levels of evidence were not extracted.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.